FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1623587890> ?p ?o ?g. }

• W1623587890 endingPage "2052" @default.
• W1623587890 startingPage "2045" @default.
• W1623587890 abstract "Summary. Background: Thromboprophylaxis with rivaroxaban (R) is superior to enoxaparin in patients undergoing major orthopedic surgery (MOS). However, rivaroxaban has never been directly compared with fondaparinux (F), which also shows superior efficacy over enoxaparin. The clinical impact of switching from fondaparinux to rivaroxaban thromboprophylaxis is unclear.Objectives:To evaluate the efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in unselected patients undergoing MOS.Patients/Methods:This is a monocentric, retrospective cohort study in 5061 consecutive patients undergoing MOS at our centre, comparing rates of symptomatic VTE, bleeding and surgical complications, length of hospital stay and risk factors for VTE.Results:Rates of symptomatic VTE were 5.6% (F) and 2.1% (R; P < 0.001), with rates for distal DVT being 3.9 vs. 1.1% (P< 0.001). Rates of major VTE were numerically higher with fondaparinux (1.8 vs. 1.1%), but not statistically significant. Rates of severe bleeding (bleeding leading to surgical revision or death, occurring in a critical site, or transfusion of at least two units of packed red blood cells) were statistically lower with rivaroxaban compared with fondaparinux (2.9 vs. 4.9%; P= 0.010). The mean length of hospital stay was significantly shorter in the rivaroxaban group (8.3 days, 95% CI 8.1–8.5 vs. 9.3 days, 9.1–9.5; P< 0.001).Conclusion:Based on an indirect comparison of two consecutive cohorts, our data suggest that thromboprophylaxis with rivaroxaban is associated with less VTE and bleeding events than fondaparinux in unselected patients undergoing MOS. Prospective comparisons are warranted to confirm our findings. Summary. Background: Thromboprophylaxis with rivaroxaban (R) is superior to enoxaparin in patients undergoing major orthopedic surgery (MOS). However, rivaroxaban has never been directly compared with fondaparinux (F), which also shows superior efficacy over enoxaparin. The clinical impact of switching from fondaparinux to rivaroxaban thromboprophylaxis is unclear. To evaluate the efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in unselected patients undergoing MOS. This is a monocentric, retrospective cohort study in 5061 consecutive patients undergoing MOS at our centre, comparing rates of symptomatic VTE, bleeding and surgical complications, length of hospital stay and risk factors for VTE. Rates of symptomatic VTE were 5.6% (F) and 2.1% (R; P < 0.001), with rates for distal DVT being 3.9 vs. 1.1% (P< 0.001). Rates of major VTE were numerically higher with fondaparinux (1.8 vs. 1.1%), but not statistically significant. Rates of severe bleeding (bleeding leading to surgical revision or death, occurring in a critical site, or transfusion of at least two units of packed red blood cells) were statistically lower with rivaroxaban compared with fondaparinux (2.9 vs. 4.9%; P= 0.010). The mean length of hospital stay was significantly shorter in the rivaroxaban group (8.3 days, 95% CI 8.1–8.5 vs. 9.3 days, 9.1–9.5; P< 0.001). Based on an indirect comparison of two consecutive cohorts, our data suggest that thromboprophylaxis with rivaroxaban is associated with less VTE and bleeding events than fondaparinux in unselected patients undergoing MOS. Prospective comparisons are warranted to confirm our findings." @default.
• W1623587890 created "2016-06-24" @default.
• W1623587890 creator A5001881012 @default.
• W1623587890 creator A5004003194 @default.
• W1623587890 creator A5007469094 @default.
• W1623587890 creator A5011448945 @default.
• W1623587890 creator A5019298730 @default.
• W1623587890 creator A5038833411 @default.
• W1623587890 creator A5054998507 @default.
• W1623587890 creator A5072985354 @default.
• W1623587890 date "2012-10-01" @default.
• W1623587890 modified "2023-10-06" @default.
• W1623587890 title "Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO‐TEP registry" @default.
• W1623587890 cites W1504831421 @default.
• W1623587890 cites W1552248059 @default.
• W1623587890 cites W1590960449 @default.
• W1623587890 cites W1851078690 @default.
• W1623587890 cites W2001029934 @default.
• W1623587890 cites W2015712245 @default.
• W1623587890 cites W2022932023 @default.
• W1623587890 cites W2034466845 @default.
• W1623587890 cites W2064859196 @default.
• W1623587890 cites W2098108939 @default.
• W1623587890 cites W2124465753 @default.
• W1623587890 cites W2132540873 @default.
• W1623587890 cites W2142836985 @default.
• W1623587890 cites W2153988016 @default.
• W1623587890 cites W2154183176 @default.
• W1623587890 cites W2757596200 @default.
• W1623587890 cites W2989714602 @default.
• W1623587890 cites W3016782834 @default.
• W1623587890 cites W4211038839 @default.
• W1623587890 doi "https://doi.org/10.1111/j.1538-7836.2012.04877.x" @default.
• W1623587890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22882706" @default.
• W1623587890 hasPublicationYear "2012" @default.
• W1623587890 type Work @default.
• W1623587890 sameAs 1623587890 @default.
• W1623587890 citedByCount "24" @default.
• W1623587890 countsByYear W16235878902013 @default.
• W1623587890 countsByYear W16235878902014 @default.
• W1623587890 countsByYear W16235878902015 @default.
• W1623587890 countsByYear W16235878902016 @default.
• W1623587890 countsByYear W16235878902017 @default.
• W1623587890 countsByYear W16235878902018 @default.
• W1623587890 countsByYear W16235878902021 @default.
• W1623587890 countsByYear W16235878902022 @default.
• W1623587890 countsByYear W16235878902023 @default.
• W1623587890 crossrefType "journal-article" @default.
• W1623587890 hasAuthorship W1623587890A5001881012 @default.
• W1623587890 hasAuthorship W1623587890A5004003194 @default.
• W1623587890 hasAuthorship W1623587890A5007469094 @default.
• W1623587890 hasAuthorship W1623587890A5011448945 @default.
• W1623587890 hasAuthorship W1623587890A5019298730 @default.
• W1623587890 hasAuthorship W1623587890A5038833411 @default.
• W1623587890 hasAuthorship W1623587890A5054998507 @default.
• W1623587890 hasAuthorship W1623587890A5072985354 @default.
• W1623587890 hasBestOaLocation W16235878901 @default.
• W1623587890 hasConcept C126322002 @default.
• W1623587890 hasConcept C141071460 @default.
• W1623587890 hasConcept C167135981 @default.
• W1623587890 hasConcept C2776301958 @default.
• W1623587890 hasConcept C2776877702 @default.
• W1623587890 hasConcept C2778661090 @default.
• W1623587890 hasConcept C2779161974 @default.
• W1623587890 hasConcept C2780868729 @default.
• W1623587890 hasConcept C2991741193 @default.
• W1623587890 hasConcept C42219234 @default.
• W1623587890 hasConcept C68312169 @default.
• W1623587890 hasConcept C71924100 @default.
• W1623587890 hasConceptScore W1623587890C126322002 @default.
• W1623587890 hasConceptScore W1623587890C141071460 @default.
• W1623587890 hasConceptScore W1623587890C167135981 @default.
• W1623587890 hasConceptScore W1623587890C2776301958 @default.
• W1623587890 hasConceptScore W1623587890C2776877702 @default.
• W1623587890 hasConceptScore W1623587890C2778661090 @default.
• W1623587890 hasConceptScore W1623587890C2779161974 @default.
• W1623587890 hasConceptScore W1623587890C2780868729 @default.
• W1623587890 hasConceptScore W1623587890C2991741193 @default.
• W1623587890 hasConceptScore W1623587890C42219234 @default.
• W1623587890 hasConceptScore W1623587890C68312169 @default.
• W1623587890 hasConceptScore W1623587890C71924100 @default.
• W1623587890 hasIssue "10" @default.
• W1623587890 hasLocation W16235878901 @default.
• W1623587890 hasLocation W16235878902 @default.
• W1623587890 hasOpenAccess W1623587890 @default.
• W1623587890 hasPrimaryLocation W16235878901 @default.
• W1623587890 hasRelatedWork W1623587890 @default.
• W1623587890 hasRelatedWork W2016079189 @default.
• W1623587890 hasRelatedWork W2183846025 @default.
• W1623587890 hasRelatedWork W2530430358 @default.
• W1623587890 hasRelatedWork W2603244127 @default.
• W1623587890 hasRelatedWork W2762394949 @default.
• W1623587890 hasRelatedWork W3030286732 @default.
• W1623587890 hasRelatedWork W4233016836 @default.
• W1623587890 hasRelatedWork W4385759020 @default.
• W1623587890 hasRelatedWork W3142495051 @default.
• W1623587890 hasVolume "10" @default.
• W1623587890 isParatext "false" @default.

• next